Oxytocin Attenuates Metabolic Dysfunction-associated Steatotic Liver Disease via AMPK/SREBP1c/FAS-mediated Suppression of Hepatic Lipogenesis
The findings demonstrate that OXT may serve as a potential therapeutic agent for MASLD by regulating the AMPK/SREBP1c/FAS pathway in lipid metabolism.
Authors
- Qin Jin (ORCID: https://orcid.org/0000-0002-7246-4651)
- Siqian Lu
- Haifeng Wu
- Hongpei Wu
- Lishuai Qu
- Yue Xu (ORCID: https://orcid.org/0000-0003-4205-5109)
- Ting Chen (ORCID: https://orcid.org/0000-0002-7946-2165)
- Xun Wang (ORCID: https://orcid.org/0000-0002-6363-4225)
- Min Li (ORCID: https://orcid.org/0000-0002-7113-2700)
- Jinxia Liu (ORCID: https://orcid.org/0000-0001-8327-2228)
- Meng Zhou (ORCID: https://orcid.org/0009-0007-8541-2782)
Institutions
- Dalian Medical University (CN)
- Nantong University (CN)
- Affiliated Hospital of Nantong University (CN)
- The Fifth People’s Hospital of Suzhou (CN)
Publication Details
- Journal
- Journal of Clinical and Translational Hepatology
- Published
- 2025-11-26
- DOI
- https://doi.org/10.14218/jcth.2025.00213
- Primary Topic
- Neuroendocrine regulation and behavior
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- National Natural Science Foundation of China
- China Postdoctoral Science Foundation
- Government of Jiangsu Province
- Natural Science Foundation of Jiangsu Province
- Nantong University